Diana Vania, MSc
Articles
June 14th 2019
Understanding Price Growth in the Market for Targeted Oncology Therapies
Jesse Sussell, PhD Jacqueline Vanderpuye-Orgle, PhD Diana Vania, MSc Hans-Peter Goertz, MPH Darius Lakdawalla, PhD
The prices of targeted oncology therapies have grown substantially, but revenues have not. This is due in part to large declines in per-drug patient counts.
Latest Updated Articles
Published: June 27th 2025 | Updated: July 1st 2025
Report Reveals Mounting Burdens of Drug Shortages on US Health System
Published: February 20th 2025 | Updated: February 21st 2025
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP
Published: January 16th 2025 | Updated: January 29th 2025
FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
